Alimta does not cure lung cancer … makes you live longer by 3 months

SINGAPORE – The Health Sciences Authority (HSA) has recently approved the use of Alimta as the latest chemotherapy drug for patients battling advanced non-squamous non-small cell lung cancer.

Lung cancer is the most common cancer in the world, causing nearly 1.4 million deaths annually.

Locally, it is the second most common cancer in males and the third most common for females. It is also the most deadly, contributing to one out of every five cancer-related deaths.

Non-small cell lung cancer is the most common type of lung cancer and the majority of patients are usually already in Stages III or IV when first diagnosed with the disease, meaning that the cancer has spread to nearby tissue and other parts of the body such as the brain or liver.

Approved in October 2012, Alimta allows patients to live for a longer period of time with the disease (about four months longer) without having it worsen, giving them a better quality of life than if they are not on maintenance therapy.

Furthermore, a trial has also showed that Stage IV non-squamous non-small cell lung cancer patients treated with Alimta were 22 per cent less likely to die from the cancer and lived close to three months longer.

Read more:


Author: CA Care

In obedience to God's will and counting on His mercies and blessings, and driven by the desire to care for one another, we seek to provide help, direction and relief to those who suffer from cancer.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s